Calliditas Therapeutics AB
calliditas.seNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2023 20-F, filed Apr 24, 2024. Its latest SEC filing is a 15F-12B from Sep 23, 2024.
20-F for FY2023, filed Apr 24, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Sells TARPEYO, a treatment for IgAN, through specialty pharmacies and licenses Nefecon to pharmaceutical partners; develops drug candidates for kidney, liver and cancer conditions.
20-F for FY2023, filed Apr 24, 2024The US Food and Drug Administration, or FDA, approved Nefecon under the brand name TARPEYO under accelerated approval on December 15, 2021…View ↗
We retain worldwide rights to Nefecon other than in territories where we have established strategic collaborations. In 2019, we entered…View ↗
We are also developing a novel platform of nicotinamide adenine dinucleotide phosphate, or NADPH, oxidase, or NOX, inhibitors, which we…View ↗
Revenue from product sales is recognized at the transaction price of goods sold excluding sales tax, rebates and returns. At the time of…View ↗
Who Were Their Customers?
Specialty pharmacies buy TARPEYO for dispensing to patients, while pharmaceutical partners license Nefecon for commercialization in Europe, China, Singapore, South Korea and Japan. Calliditas markets TARPEYO independently in the United States through a targeted sales team.
20-F for FY2023, filed Apr 24, 2024Revenue from product sales is recognized at the transaction price of goods sold excluding sales tax, rebates and returns. At the time of…View ↗
We retain worldwide rights to Nefecon other than in territories where we have established strategic collaborations. In 2019, we entered…View ↗
Maximize the potential of Nefecon, where approved, through commercialization independently and through collaborations with third parties.…View ↗
Did Revenues Turn Into Profits?
No. It lost SEK 466.2M in .
20-F for FY2023, filed Apr 24, 2024
Who Did They Compete With?
Competes with Travere Therapeutics, Novartis, Roche, Ionis Pharmaceuticals, Vera Therapeutics, Otsuka, Alpine Immune Sciences, BioCryst, Arrowhead Pharmaceuticals, Takeda, Alnylam Pharmaceuticals, AstraZeneca, Alexion Pharmaceuticals, DiaMedica Therapeutics, MorphoSys, Kira Pharma, Intercept Pharmaceuticals, Cymabay Therapeutics, Ipsen, and GENFIT
20-F for FY2023, filed Apr 24, 2024In February 2023, the FDA conditionally approved FILSPARI (sparsentan), an orally-administered small molecule indicated to reduce…View ↗
Loading...
